Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs

NYSE:PFE

Pfizer Inc (PFE)

26.17
+0.57 (2.23%)
as of Jun 11, 2026, 8:00:00 pm Market Open.
322 watching
0
BUY
Although they have drugs coming off patent over the next few years, they are acquiring wyeth and they have some promising new drugs.
TOP PICK
Pharmaceutical industry has been very much out of favour. Likes the long-term play in pharmaceuticals with the aging population and demographics. Recently bought Wyeth (WYE-N) and expecting a lot of synergies from this. Trades at 8.5X earnings with almost 4% dividends.
BUY
Good performer in the last 6 to 7 months. Decent yield. Problem with all major pharma stocks are the products coming off patent requiring new avenues for growth. Acquired Wyeth (WYE-N), which has fewer drugs coming off patent and more coming on line. (Also owns Teva for their generic drugs.)
DON'T BUY
This will depend on what the US president comes up with on a healthcare plan. Until that is resolved all the drug stocks will be under pressure.
DON'T BUY
Largest drug company globally. Very strong number of products but along with most of the big pharmaceutical companies there are a large number of drugs that come off patent. About 25% of their earnings comes from one drug, Lipitor and when it comes off patent it will have a big effect on their earnings. There are better places to be.
DON'T BUY
This is not the one to bet on in this sector. Very cheap, up for a reason. Drug pipeline is not impressive. Have patent issues. (See Top Picks.)
COMMENT
Recently started buying through selling Put options, which would require him to Buy (e.g. at $16). Tide is turning on the sector and he likes it very much. Risks are healthcare reform and patent expirations.
DON'T BUY
There will continue to be pressure on prices. Also US government is litigation friendly, which can hit them with 1) injury related suits and 2) patent infringement.
HOLD
Reflects all the bad news that Lipitor will be going going off patent in a couple of years and its drug pipeline is absolutely barren. In the meantime you get paid 6.5%. Pretty cheap.
TOP PICK
Thinks the pharmaceutical sector will start to do quite well in the next 2 years. It is so negative now in terms of what the government wants to do but historically they have never been able to cut the price of drugs. You are getting 5% to wait.
DON'T BUY
Not a fan of big cap pharma and hasn't been for some time. One of the most difficult business models to operate. Regulatory issues are so difficult to overcome between patent expiries and increasingly stringent health regulations and registration processes. (See Top Picks.)
SELL
The major pharmaceuticals are not on his top list. Bioteches are where you are going to see innovations. They are the ones coming out with the new drugs and have a better pipeline.
DON'T BUY
Just doesn't seem to be up to right itself. Spinning off a lot of cash but its size limits it from growing.
DON'T BUY
Getting killed by generics. They get sued when they hurt people. Government won't stand up for them when generics can provide health care at a fraction of the price. Prefer TEVA-O
DON'T BUY
Has been a difficult stock. Could improve from here however there will be other opportunities in this space you could get more juice from.
Showing 391 to 405 of 801 entries